Prominent publications by Esteban Martínez

KOL Index score: 18158

Current treatment guidelines for HIV infection recommend a relatively late initiation of highly active antiretroviral therapy (HAART). Nevertheless, there is still a concern that immune recovery may not be as complete once CD4+ T cells have decreased below a certain threshold. This study addressed the long-term response of CD4+ T-cell counts in patients on HAART and analyzed the influence of baseline CD4+ T-cell counts, baseline viral load, and age. An observational analysis of evolution ...

Also Ranks for: Cd4 Cells |  cell count |  highly active |  patients haart |  antiretroviral therapy
KOL Index score: 16395

BACKGROUND: We assessed the strategy of substituting nevirapine, efavirenz, or abacavir for a protease inhibitor in patients infected with human immunodeficiency virus type 1 (HIV-1) in whom virologic suppression had been achieved.

METHODS: We randomly assigned 460 adults who were taking two nucleoside reverse-transcriptase inhibitors and at least one protease inhibitor and whose plasma HIV-1 RNA levels had been less than 200 copies per milliliter for at least the previous six months to ...

Also Ranks for: Protease Inhibitor |  nevirapine efavirenz |  virologic failure |  study medication |  human immunodeficiency
KOL Index score: 15832

BACKGROUND: Prophylaxis against Pneumocystis carinii pneumonia is indicated in patients with human immunodeficiency virus (HIV) infection who have less than 200 CD4 cells per cubic millimeter and in those with a history of P. carinii pneumonia. However, it is not clear whether prophylaxis can be safely discontinued after CD4 cell counts increase in response to highly active antiretroviral therapy.

METHODS: We conducted a randomized trial of the discontinuation of primary or secondary ...

Also Ranks for: Carinii Pneumonia |  secondary prophylaxis |  hiv infection |  highly active |  pneumocystis rna
KOL Index score: 14176

BACKGROUND: The incidence and severity of coronavirus disease 2019 (COVID-19) among HIV-positive persons receiving antiretroviral therapy (ART) have not been characterized in large populations.

OBJECTIVE: To describe the incidence and severity of COVID-19 by nucleos(t)ide reverse transcriptase inhibitor (NRTI) use among HIV-positive persons receiving ART.

DESIGN: Cohort study.

SETTING: HIV clinics in 60 Spanish hospitals between 1 February and 15 April 2020.

PARTICIPANTS: 77 590 ...

Also Ranks for: Antiretroviral Therapy |  severity covid19 |  tdf ftc |  positive persons |  hiv infections
KOL Index score: 13387

BACKGROUND: Current therapies for chronic hepatitis C virus (HCV) in HIV co-infected patients have a low success rate and are poorly tolerated. We have evaluated the efficacy and safety of interferon alfa-2b (IFN) + ribavirin (RBV) versus pegylated interferon alfa-2b (PEG-INF) + RBV.

METHODS: Randomized, single-centre, open-label clinical trial including patients with: detectable HCV-RNA, alanine aminotransferase > 1.5-fold upper limit of normal, abnormal liver histology, CD4 cell count ...

Also Ranks for: Ribavirin Treatment |  infected patients |  infections hepatitis |  genotypes svr |  hiv rna
KOL Index score: 13360

BACKGROUND: Switching to raltegravir in selected patients treated with ritonavir-boosted protease inhibitors may result in similar efficacy and lower plasma lipids.

METHODS: SPIRAL is a 48-week multicentre, open-label trial in which HIV-infected adults with less than 50 copies/ml of plasma HIV RNA for at least the previous 6 months on ritonavir-boosted protease inhibitor-based therapy were randomized (1: 1) to switch from the ritonavir-boosted protease inhibitor to raltegravir or to ...

Also Ranks for: Boosted Protease |  infected patients |  spiral study |  48 weeks |  treatment failure
KOL Index score: 12780

BACKGROUND: Risk factors for lipodystrophy in patients infected with HIV-1 treated with highly active antiretroviral therapy (HAART) containing HIV-1 protease inhibitors are poorly understood. We aimed to identify the risk factors for lipodystrophy in antiretroviral-naive HIV-1-infected adults on HAART.

METHODS: Moderate or severe body-fat changes were clinically assessed and categorised as subcutaneous lipoatrophy, central obesity, or both, in all consecutive antiretroviral-naïve ...

Also Ranks for: Central Obesity |  infected patients |  risk factors lipodystrophy |  protease inhibitors |  6 months
KOL Index score: 12636

BACKGROUND: The role of viruses in community-acquired pneumonia may have been previously underestimated. We aimed to study the incidence and clinical characteristics of community-acquired pneumonia (CAP) due to respiratory viruses in adults adding PCR to routine conventional laboratory tests.

METHODS: Consecutive adult patients diagnosed of CAP from January 2003 to March 2004 were included. Conventional tests including cultures of blood, sputum, urine antigen detection of Streptococcus ...

Also Ranks for: Respiratory Viruses |  acquired pneumonia |  nasopharyngeal swabs |  viral community |  aetiology cap
KOL Index score: 12516

OBJECTIVES: To assess the effects of switching from HIV-1 protease inhibitors (PI) to nevirapine on metabolic abnormalities in patients with fat redistribution and on CD4 T lymphocytes and plasma HIV-1 RNA.

DESIGN: Longitudinal data analysis of 23 consecutive patients treated with two nucleoside reverse transcriptase inhibitors and at least one PI who decided to stop PI despite sustained virological suppression (< 200 copies/ml) because of psychological repercussions caused by body ...

Also Ranks for: Metabolic Abnormalities |  hiv1 rna |  nevirapine patients |  cholesterol triglycerides |  200 copies
KOL Index score: 12498

OBJECTIVES: To evaluate the efficacy and safety of switching from boosted lopinavir (LPV/r) to boosted atazanavir (ATV/r) in virologically suppressed HIV-1-infected patients versus continuing LPV/r.

METHODS: Forty-eight weeks analysis of a randomized, open-label, noninferiority trial including patients with virological suppression (< or = 200 copies/mL for > or = 6 months) on LPV/r-containing triple highly active antiretroviral therapy. Patients (n = 248) were randomized 1:1 either to ...

Also Ranks for: Boosted Atazanavir |  virological suppression |  atv arm |  lpv patients |  antiretroviral therapy
KOL Index score: 12064

INTRODUCTION: GESIDA and the Spanish National AIDS Plan panel of experts have recommended preferred (PR), alternative (AR) and other regimens (OR) for antiretroviral therapy (ART) as initial therapy in HIV-infected patients for 2017. The objective of this study was to evaluate the costs and the efficiency of initiating treatment with PR and AR.

METHODS: Economic assessment of costs and efficiency (cost-efficacy) based on decision tree analyses. Efficacy was defined as the probability of ...

Also Ranks for: Costs Art |  antiretroviral therapy |  efficiency treatment |  48 weeks |  national aids
KOL Index score: 11779

BACKGROUND: : Switching from boosted protease inhibitors (PI/r) to raltegravir (RAL) results in a better plasma lipid profile than continuing PI/r. Whether this strategy affects plasma biomarkers associated with atherosclerosis is unknown.

METHODS: : We assessed 48-week changes in fasting lipids and several biomarkers including serum high-sensitivity C-reactive protein (hsCRP), monocyte chemoattractant protein 1 (MCP-1), osteoprotegerin, interleukin (IL) 6, IL-10, tumor necrosis factor ...

Also Ranks for: Protease Inhibitors |  cardiovascular biomarkers |  patients switching |  48 weeks |  raltegravir ral
KOL Index score: 11495

BACKGROUND: Pre-eclampsia and/or fetal death have increased sharply in HIV-infected pregnant women receiving HAART.

METHODS: The occurrence of pre-eclampsia or fetal death was analysed in women who delivered after at least 22 weeks of gestation for all women (January 2001 until July 2003) and for HIV-infected women (November 1985 until July 2003).

RESULTS: In 2001, 2002 and 2003, the rates per 1000 deliveries of pre-eclampsia and fetal death, respectively, remained stable in all pregnant ...

Also Ranks for: Pregnant Women |  highly active |  eclampsia pregnancy |  antiretroviral therapy |  hiv infected
KOL Index score: 11423

Streptococcus pneumoniae is suspected to cause an important proportion of community-acquired pneumonia (CAP) whose aetiology cannot be detected with conventional tests. In this study, the authors evaluated the diagnostic yield of a new immunochromatographic membrane test (ICT) for the detection of the S. pneumoniae antigen in the urine of patients admitted with diagnosed CAP. ICT was performed in unconcentrated and concentrated urine from all the patients. ICT was repeated 1 month after ...

Also Ranks for: Antigen Test |  pneumococcal community |  patients ict |  acquired pneumonia |  diagnostic yield

Key People For Antiretroviral Therapy

Top KOLs in the world
Andrew * *********
antiretroviral therapy viral load hiv infection
Jens ******* ********
antiretroviral therapy hiv infection viral load
Peter ******
antiretroviral therapy hiv infection myocardial infarction
David * ******
antiretroviral therapy hiv infection viral load
Joseph * ****
antiretroviral therapy united states hiv infection
Douglas * ********
antiretroviral therapy hiv infection human immunodeficiency virus

Esteban Martínez:Expert Impact

Concepts for whichEsteban Martínezhas direct influence:Antiretroviral therapy,  Infected patients,  Hivinfected patients,  Hiv infection,  Protease inhibitors,  Anorexia nervosa,  Protease inhibitor,  Hiv infections.

Esteban Martínez:KOL impact

Concepts related to the work of other authors for whichfor which Esteban Martínez has influence:Antiretroviral therapy,  Hiv infection,  Human immunodeficiency virus,  Infected patients,  Protease inhibitors,  Insulin resistance,  Highly active.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

University Hospital of Barcelona, Barcelona, Spain | Infectious Diseases Service, HIV Unit, Hospital Clinic and IDIBAPS, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain | Infectious Diseases Service, Hospital Clinic/IDIBAPS, Barcelon